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Abstract
Rationale Stressful life events are suggested to contribute to the development of various pathologies, such as cardiovascular
disorders, whose etiopathogenesis is highly associated with elevated levels of serum amyloid A (SAA) proteins. SAA synthesis
in the liver is regulated by a complex network of cytokines acting independently or in concert with various hormones/stimulants
including the stress-activated sympathetic nervous system.
Objective This study aims to investigate the underlying mechanisms that regulate the stress-induced hepatic synthesis of SAA,
with particular focus on adrenoceptors (AR), major components of the sympathoadrenal response to stress.
Methods and results We demonstrated that repeated stress elevates IL-1β, IL-6, and TNFα serum levels in mice, accompanied
by increased synthesis and secretion of hepatic SAA1/2 and SAA3, an effect that was blocked by AR antagonists. Moreover,
stimulation of α1- and β1/2-ARs mimics the stress effect on SAA1/2 regulation, whereas α2-AR stimulation exhibits a relatively
weak impact on SAA. In support of the essential cytokine contribution in the AR-agonist induced SAA production is the fact that
the anti-inflammatory drug, sodium salicylate, prevented the AR-stimulated hepatic SAA1/2 synthesis by reducing IL-1β levels,
whereas IL-1β inhibition with Anakinra mimics this sodium salicylate preventive effect, thus indicating a crucial role for IL-1β.
Interestingly, the AR-driven SAA3 synthesis was elevated by sodium salicylate in a TNFα-dependent way, supporting diverse
and complex regulatory roles of cytokines in SAA production. In contrast to α1/α2-AR, the β1/2-AR-mediated SAA1/2 and
SAA3 upregulation cannot be reversed by fenofibrate, a hypolipidemic drug with anti-inflammatory properties.
Conclusion Taken together, these findings strongly support a critical role of the AR-stimulated inflammatory response in the
hepatic SAA production under stressful conditions, highlighting distinct AR type-specific mechanisms that regulate the hepatic
synthesis of SAA1/2 and SAA3.
Keywords SAA1/2 . SAA3 . Stress . Adrenoceptors . IL-1β . IL-6 . TNFα
Introduction
Clinical and experimental evidence suggests that environmen-
tal stress and stressful life events contribute to the develop-
ment of various pathologies whose aetiopathogenesis is high-
ly associated with elevated levels of serum amyloid A (SAA)
proteins (Dong et al. 2011; Marzi et al. 2013; Miyazaki et al.
2016; Ye and Sun 2015) (Johnson et al. 2004; O’Brien et al.
2005; Ridker et al. 1998). For instance, SAA mediates the
retention of high- and low-density lipoproteins on vascular
extracellular matrix and thus, favors atherogenesis by increas-
ing cholesterol deposition in plaques; a condition associated
with increased risk for cardiovascular disorders (Artl et al.
2000; Malle and De Beer 1996; O’Brien et al. 2005).
Moreover, the longstanding overproduction of SAA is
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00213-018-5149-4) contains supplementary
material, which is available to authorized users.
* Maria Konstandi
mkonstan@cc.uoi.gr
1 Faculty of Medicine, Department of Pharmacology, University of
Ioannina, Ioannina, Greece
2 Laboratory of Metabolism, National Cancer Institute, National
Institutes of Health, Bethesda, MD, USA
3 Life and Health Sciences Research Institute (ICVS), Medical School,
University of Minho, Braga, Portugal
4 ICVS/3B’s - PT Government Associate Laboratory, Braga, Portugal
5 Graduate School of Medicine, Department of Anatomy and
Regenerative Biology, Osaka City University, Osaka, Japan
Psychopharmacology
https://doi.org/10.1007/s00213-018-5149-4
connected with the pathogenesis of systemic AA amyloidosis,
which is found in chronic inflammatory, neoplastic, and infec-
tious diseases. In systemic amyloidosis, the fibril proteins are
alpha amyloid proteins (AA amyloids), formed by proteolytic
splitting of SAA, and deposit in organs, such as the liver
(Husebekk et al. 1985; Kisilevsky 1983; Pettersson et al.
2008; Skogen et al. 1980; Sletten and Husby 1974). It has
been reported that excessive deposition of AA amyloids into
systemic organs could result in organ failure or even become
fatal (Jayaraman et al. 2017; Kingman and Pereira 2001; Nishi
et al. 2008).
SAA proteins are secreted during the acute phase of in-
flammation and are considered as pleotropic. They serve
several roles including the recruitment of immune cells to
inflammatory sites, the activation of NF-kB and other tran-
scription factors, the modification of the lifespan of neutro-
phils, the transport of cholesterol to liver and secretion to
bile, as well as the induction of enzymes mediating the
degradation of extracellular matrix (Ye and Sun 2015;
Zhang et al. 2005). SAA1–SAA3 are the major acute phase
reactants in mice (O’Brien et al. 2005; Zhang et al. 2005)
synthesized in the liver and increased up to 1000-fold upon
exposure to acute inflammatory stimulus (Lee et al. 2017;
Malle and De Beer 1996; O’Brien et al. 2005; Steel and
Whitehead 1994). The major stimulators of SAA synthesis
in the liver are the pro-inflammatory cytokines, with inter-
leukin 1β (IL-1β), hepatocyte stimulating factor/interleukin
6 (IL-6), and tumor necrosis factor alpha (TNFα) being
among the critical ones (Cray et al. 2013; Gabay and
Kushner 1999; Jacobsen and Andersen 2007; Lee et al.
2017). Several diverse factors may regulate the immune re-
sponse in humans and animals, with stress holding a critical
role. Individuals exposed to stress show increased morbidity,
which has been attributed, in part, to impaired function of
their immune system (Chrousos 2009; Johnson et al. 1992).
Previous studies demonstrated a cross-talk between the im-
mune system and autonomous nervous system, with both the
hypothalamic-pituitary-adrenal axis and the sympathetic ner-
vous system (SNS) playing a critical role. Upon SNS acti-
vation by stress, catecholamines such as epinephrine and
norepinephrine, are secreted from the adrenal medulla and
sympathetic nerve terminals (Chrousos 2009; Johnson et al.
1992; Nicolaides et al. 2015) and induce their pleiotropic
effects via stimulation of adrenoceptors (ARs). In particular,
catecholamines target lymphocytes and phagocytes that ex-
press different ARs, thus triggering a general immune and
pro-inflammatory mediator response (Johnson et al. 2005).
Moreover, catecholamines are also secreted from these im-
mune cells and act in an autocrine/paracrine fashion regulat-
ing phagocytes and affect lymphocyte trafficking and cyto-
kine production, among others, via stimulation of α1/α2/β2-
ARs (Flierl et al. 2009; Nicolaides et al. 2015; Spengler
et al. 1990, 1994; Tan et al. 2007).
However, the interplay of stress and in particular, of
SNS in the immune response and SAA regulation, remains
complex and poorly understood. For instance, previous
studies report controversial evidence on the SNS effects
on different components of the immune system (Elenkov
et al. 2000; Flierl et al. 2009; Madden et al. 1989), while
the role of stress on SAA regulation remains unclear, with
several studies reporting either an up- or down-regulating
stress-driven impact (Aich et al. 2009; McConnell et al.
2009). Therefore, the present study investigates the effect
of stress, a major activator of SNS, on the regulation of
SAA in the liver focusing on AR-linked pathways, major
components of the sympathoadrenal response to stress
(Cruise et al. 1987; Lalchandani et al. 2004; Minneman
and Esbenshade 1994; Virtanen 1989).
Materials and methods
Animals
Male SV129mice (9 weeks old) were housed in a temperature
and light-controlled environment. Standard rodent chow and
tap water were provided ad libitum. Animals were adapted to
handling for an adaptation period of 1 week prior to the ex-
periment. Ethics approval statement: all procedures were car-
ried out in accordance with Institute of Laboratory Animal
Resources (USA) guidelines and approved prior to the initia-
tion of this study by the National Cancer Institute Animal Care
and Use Committee. They also conformed to the International
European Ethical Standards (86/609-EEC) for the care and
use of laboratory animals.
Stress paradigm
In an isolated environment, experimental animals were
exposed to restraint stress 2 h daily for 4 consecutive days
(Konstandi et al. 2004). Throughout the stress, animals
were restricted to adequately ventilated individual 50-mL
conical plastic tubes (3 × 10 cm modified Falcon tubes).
During the stress task, no pain and physical squeezing
were applied to the animals. They were allowed to rotate
from supine to prone position, but they could not turn
head to tail. Non-stressed controls were left undisturbed
in their home cages, but food and water were removed for
2 h to match the stress group.
Drugs and treatment
The α1-AR agonist, phenylephrine hydrochloride (Sigma-
Aldrich, 2 mg/kg) and the β1/2-AR agonist, isoprenaline
hydrochloride (Sigma-Aldrich, 2 mg/kg) were adminis-
tered intraperitoneally for 4 consecutive days. The α2-AR
Psychopharmacology
agonist, dexmedetomidine hydrochloride (Dexdomitor,
Orion Pharma-Pfizer, USA, 5 μg/kg) was given subcutane-
o u s l y f o r 4 c o n s e c u t i v e d a y s . T h e d o s e o f
dexmedetomidine was chosen in order to avoid sedation.
Epinephrine (Sigma-Aldrich, α/β-AR agonist) was admin-
istered daily for 4 consecutive days in the optimal dose
(0.5 mg/kg, s.c.) to avoid cardiovascular implications.
Prazosin hydrochloride (α1-AR antagonist; Sigma-
Aldrich, 20 mg/kg i.p) or atipamezole hydrochloride (α2-
AR antagonist; Antisedan, Orion Pharma, Pfizer,
200 μg/kg s.c.), were administered 30 min prior to stress.
Propranolol hydrochloride (β1/2-AR antagonist; Sigma-
Aldrich, 10 mg/kg, i.p.) was administered 15 min before
stress. The dosages of the AR-agonists were selected ac-
cording to the literature to achieve sufficient stimulation of
the adrenoceptors (Virtanen 1989), while preserving all an-
imals healthy throughout the experiment. Sodium salicylate
(Sigma, 200 mg/kg i.p.) was administered 30 min before
the AR-agonists. Mice also received Anakinra (IL-1β an-
tagonist; Kineret, Sobi Swedish Orphan Biovitrum; total
300 mg/kg s.c.) prior to treatment with sodium salicylate
and AR-agonists. More specifically, the treatment of mice
started with Anakinra alone (100 mg/kg s.c.) in the morn-
ing, followed by 50 mg/kg s.c. Anakinra each time before
the combined treatment containing sodium salicylate and
AR agonist. Another group of animals was treated with
Infliximab (TNFα inhibitor, Remicade, Centocor, USA;
10 mg/kg s.c., once daily, total 20 mg/kg) administered
1 h before the first sodium salicylate injection of the day.
Control animals of the last two experimental series received
the vehicle containing 500 mg sucrose, 0.5 mg polysorbate-
80, 2.2 mg monobasic sodium phosphate monohydrate, and
6.1 mg dibasic sodium phosphate dihydrate per 10mL ster-
ile water. As sodium salicylate and all AR-agonists used in
this study were dissolved in saline, all other controls re-
ceived saline. Experimental animals were fed the normal
diet. There were also animals treated with either normal
saline (i.p.) or fenofibrate (FEN, in rodent chow 0.2%),
which also received the AR agonists. After the stress expo-
sure and 2 h after the last drug-treatment, animals were
killed by CO2 asphyxiation followed by decapitation.
Trunk blood was collected in BD Microtainer Serum
Separator Tubes (Becton, Dickinson and Company, USA)
for hormonal, biochemical and western blot analyses and
kept at − 80 °C. Liver samples were dissected for total RNA
and cellular protein extraction.
Quantitative real-time PCR
TRIZOL reagent (Invitrogen, Carlsbad, CA) was used for iso-
lation of total RNA from the tissues following the manufac-
turer’s protocol. The concentration of total RNA was deter-
mined spectrophotometrically. Quantitative real-time reverse
transcriptase PCR (qPCR) was performed with cDNA gener-
ated from 1 μg total RNAwith a SuperScript III reverse tran-
scriptase kit (Invitrogen). Gene-specific primers were de-
signed for qPCR using the Primer Express software
(Applied Biosystems, Foster City, CA). Primer sequence
(5′–3′): SAA1/2, forward: TCATGTCAGTGTAGGCTCGC,
reverse: GTCTTCTGCTCCCTGCTCC; SAA3, forward:
AGTAGGCTCGCCACATGTCT, reverse: TCCATTGC
CATCATTCTTTG; and β-actin, forward: TATTGGCA
ACGAGCGGTTCC, reverse: GGCATAGAGGTCTT
TACGGATGTC. SYBR Green PCR master mix (Applied
Biosystems, Warrington, UK) was used for the real-time reac-
tions, which were carried out using the ABIPRISM 7900 HT
sequence detection system (Applied Biosystems). The PCR
conditions were the following: 95 °C for 10 min followed
by 40 cycles of 95 °C for 15 s and 60 °C for 1 min, and 1
cycle of 95 °C for 15 s, 60 °C for 15 s, and 95 °C for 15 s.
Relative mRNA expression levels were normalized to β-actin
and values were quantified using the comparative threshold
cycle method.
Western blot analysis
Immunoblot analysis of SAA proteins was carried out
using serum samples from the treated animals. Serum
samples were subjected to fragmentation using specific
nanofilters (Pall Nanosep Omega 30K PK100, Utech
Products Inc. Schenectady, NY), which removed proteins
with molecular weight higher than 30 kDa. Protein con-
centrations were determined with a BCA protein assay kit
(Pierce, Rockford, IL). Proteins separated by sodium do-
decyl sulfate-polyacrylamide gel (15%) electrophoresis
were transferred overnight (100 mA at 4 °C) to
polyvinylidene difluoride membranes (GE Healthcare,
Piscataway, NJ). Membranes were blocked in 3% non-fat
milk in Tris-buffered saline (TBS)-Tween buffer for 1 h.
Blocked membranes were incubated in rat monoclonal
IgG2b specific for mouse SAA antibody (1:200; sc-
59,680; Santa Cruz Biotechnology, Santa Cruz, CA). The
expressions of the phospho, as well as total protein levels
of kinase Akt and the extracellular signal-regulated kinase
(Erk1/2) were analyzed in liver protein extracts using
RIPA buffer supplemented with protease inhibitors,
PMSF (10 μM), BGP (50 μM), and NaF (50 μM).
Total extracts were subjected to sodium dodecyl sulfate-
polyacrylamide gel (7%) electrophoresis and immunoblot-
ting using the phosphor and total Akt, Erk1/2 antibodies
(1:500 and 1:1000, respectively; Cell Signaling).
Immunoblotting with GAPDH antibody (1:1000, Santa
Cruz Biotechnology) was used as loading control. After
incubation with the appropriate secondary antibody (Cell
Signaling), antigens were revealed by enhanced chemilu-
minescence detection kit (ECL Clarity, Bio-Rad). Signal
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monitoring and quantification were achieved using a
BIORAD ChemiDoc and ImageLab BIORAD software.
All values were normalized and expressed as a percentage
of control values.
Hormonal and biochemical determinations
Serum IL-1β, IL-6, and TNFα levels were determined
using IL-1β EIA (R&D Systems, Minneapolis, MN), IL-
6 EIA (eBioscience Ready-SET-Go, San Diego, USA) and
TNFα OptEIA EIA (BD Biosciences-Pharmingen) kit as-
says, respectively. To assess the possible toxic effects of
the AR-agonists, serum ALT and AST levels were mea-
sured with the DiscretePak ALT and AST Reagent kits
(Catachem Inc., Bridgeport, CT), respectively. As a key
element of the neuroendocrine response to stress
(Chrousos 2009; Johnson et al. 1992), corticosterone
(CORT) levels were measured using a Corticosterone
EIA kit (Cayman Chemical Company, Ann Arbor, MI)
and found ranging from 30 to 100 pg/mL in non-stressed
controls and 160 to 300 pg/mL in stress-exposed mice
(mean ± SE; control vs. stress, 87.0 ± 21.3 vs. 226 ± 40.0,
n = 20, P < 0.001). The detection limit was about 40 pg/mL
and the intra-assay coefficient of variation (CV) was 4.1%.
Monitored by RapiTex CRP kit assay (Siemens), serum C-
reactive protein (CRP) levels were not significantly altered
by repeated stress or AR agonists. In all treatment groups,
CRP values raged at levels lower than 6 μg/mL (no agglu-
tination was observed).
Statistical analysis
All data are presented as the mean ± SE and were analyzed
using one-way analysis of variance (ANOVA) followed by
Bonferroni’s or Tukey’s post hoc analysis. Correlation analy-
sis (see Table 1) was performed using the Pearson’s coefficient
correlations. The significance level for all analyses was set at
probability of less than 0.05.
Results
Exposure to repeated stress increases SAA synthesis:
role of adrenoceptor-linked pathways
To evaluate the impact of psychophysiological stress on SAA
synthesis, mice were exposed to repeated restraint stress. We
found that repeated stress markedly increasedmRNA levels of
SAA1/2 and SAA3 isoforms in the liver of animals where
these proteins are predominantly produced (Uhlar and
Whitehead 1999) (Fig. 1a, b). Furthermore, western blot anal-
ysis revealed that restraint stress also increased total SAA
protein load in the serum (Fig. 1c, d), an effect that was ac-
companied by elevated IL-1β, IL-6, and TNFα serum levels
when compared to non-stressed controls (Fig. 1e). Along with
glucocorticoids, catecholamines released upon stress repre-
sent the major elements of the stress response (Chrousos
2009; Johnson et al. 1992; Nicolaides et al. 2015) and display
their properties by activation ofα- andβ-adrenoceptors (ARs)
(Cooper and Bloom 1996). To identify the role of catechol-
amines and α1-, α2-, and β1/2-AR in the regulation of SAA,
we next treated animals with epinephrine (Epin, α/β-AR ag-
onist) or agonists of different ARs. As shown in Fig. 2, Epin
treatment upregulated SAA1/2 and SAA3 in the liver (Fig. 2a,
b) and increased the load of SAA in the serum (Fig. 2c)
followed by increased IL-1β, IL-6, and TNFα serum levels
compared to controls (Table 2). Treatment with either phenyl-
ephrine (Ph), an α1-AR agonist, or isoprenaline (Isop), a β1/2-
AR agonist increased SAA1/2 and SAA3mRNA expression in
the liver of mice, and elevated total SAA protein load in se-
rum, when compared to controls (Fig. 2a–d), mimicking the
effects of repeated stress (compare with Fig. 1). It should be
noted that, although dexmedetomidine (Dext), an α2-AR ag-
onist, markedly increased SAA1/2 and SAA3 mRNA expres-
sion in the liver of mice, no such effect was detected at total
SAA protein load in the serum (Fig. 2c, d). Furthermore, Ph
and Isop (α1- and β1/2-AR agonist, respectively) triggered a
marked increase in serum IL-1β, IL-6, and TNFα levels
(Table 2) that was statistically correlated with SAA1/2 and
SAA3 mRNA levels (Table 1). Note that Dext (α2-AR ago-
nist) exhibited a mild effect on the above cytokines that was
not correlated with SAA levels (Tables 1 and 2). Combined
with the weaker effect of Dext on SAA1/2 and SAA3 mRNA
expression, these findings suggest that stimulation of α2-AR
alone is not able to trigger markedly SAA production and
secretion.
As the above findings clearly demonstrated the driving role
of different ARs in hepatic SAA synthesis and secretion, we
next investigated the involvement of AR-linked pathways in
the stress-induced SAA upregulation by treating mice with
either α- or β-AR-antagonists prior to stress exposure. We
found that blockade of either α1-, α2-, or β1/2-ARs with
prazosin (Pz), atipamezole (Ati), or propranolol (Prop),
Table 1 Correlation
between liver SAA
expression and serum
cytokine levels
Variables IL-1β IL-6 TNFα
Comparison: Con vs. Ph (α1-AR agonist)
SAA1/2 0.82* 0.79* 0.78*
SAA3 0.86* 0.82* 0.87*
Con vs. Dext (α2-AR agonist)
SAA1/2 0.22 0.23 0.12
SAA3 0.16 0.12 0.01
Con vs. Isop (β1/2-AR agonist)
SAA1/2 0.73* 0.78* 0.95*
SAA3 0.83* 0.80* 0.93*
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respectively, prior to stress, prevented the upregulating effect
of stress on SAA1/2 (Fig. 2e). Interestingly blockade of either
α2- or β1/2-ARs alone by Ati or Prop, respectively, prevented
the upregulating effect of stress on SAA3, whereas blockade
of α1-AR with Pz did not prevent it (Fig. 2f). Thus, the above
findings indicated that the stress-induced SAA1/2 upregula-
tion is mediated by stimulation of all types of ARs (Fig. 2e),
whereas that of SAA3 is mediated mainly by α2- and β1/2-AR
stimulation (Fig. 2f). It should be noted that the effect of AR-
agonists on SAA synthesis is not related to any toxic effect, as
ASTand ALTserum levels were not significantly modified by
the drugs used (Supplementary Table 1).
Dissecting the inflammatory signals
in adrenoceptor-mediated SAA up-regulation
To further assess the involvement of cytokines in the AR-
mediated upregulation of SAA, a different group of animals
was simultaneously treated with AR agonists and the non-
steroidal anti-inflammatory drug, sodium salicylate, known
to reduce pro-inflammatory cytokine synthesis in
macrophages (Housby et al. 1999; Vittimberga Jr. et al.
1999) and to inhibit the production of COX2/PG/PKA, down-
stream elements in IL-1β-related pathways (Schiller et al.
2006). As shown in Fig. 3, sodium salicylate prevented the
α1-, α2-, and β1/2-AR induced hepatic SAA1/2 upregulation
(Fig. 3a) that was accompanied by suppression of serum IL-
1β levels (Fig. 3b); note that serum IL-6 levels remained un-
affected [Ph vs. (Ph + sodium salicylate), 107.6 ± 19.6 vs.
103.0 ± 32.1, n = 10]. In order to clarify the potential role of
IL-1β, we next investigated the effect of Anakinra, an IL-1β
inhibitor, which blocked the AR agonist-induced SAA1/2 up-
regulation (Fig. 3c), confirming the critical role of IL-1β in the
AR-induced SAA1/2 upregulation.
Interestingly, sodium salicylate exhibited a different effect
on SAA3 synthesis when administered in combination with
AR agonists. Specifically, the combined treatment with sodi-
um salicylate and Ph (α1-AR agonist) resulted in a robust
increase in hepatic SAA3mRNA levels (Fig. 3d), which could
be related to the increased serum TNFα levels detected in this
treatment group (Fig. 3e). In support of this notion, co-
treatment of Ph + sodium salicylate with the TNFα inhibitor
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Fig. 1 Repeated restraint stress
triggers the induction and release
of serum amyloid proteins. a–d
Animals exposed to repeated
restraint stress (Str) exhibited
higher hepatic mRNA levels of
serum amyloid A1/2 (SAA1/2)
(a), serum amyloid A3 (SAA3)
(b), as well as higher serum SAA
apoprotein levels (c, d) compared
to undisturbed control animals
(Con). e In parallel, serum
cytokine levels, interleukin 1β
(IL-1β), interleukin 6 (IL-6), and
tumor necrosis factor α (TNFα),
were markedly increased in the
stressed animals compared to
controls. All numerical data are
shown as mean + SEM;
*P < 0.05, **P < 0.01,
***P < 0.001
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(Infliximab) prevented the robust upregulation of hepatic
SAA3 mRNA levels (Fig. 3f). Co-treatment of sodium salicy-
late with Dext or Isop (α2- and β1/2-AR agonist, respectively)
also increased hepatic SAA3 mRNA levels, but to a lesser
extent (Fig. 3d), and this upregulation appears to be associated
with the increased serum TNFα levels (Fig. 3e, f). In order to
further investigate the pathways underlying the sodium
salicylate-induced blockade of the AR-stimulated SAA1/2
expression, we also monitored the activation of Akt and
Erk1/2 signaling pathways that regulate SAA synthesis
(Fasshauer et al. 2004; Nguyen and Gao 1999). Western blot
analysis revealed that Ph alone reduced the levels of phos-
phorylated Akt (p-Akt), while Isop had no effect (Fig. 3g,
h). Interestingly, when sodium salicylate was provided alone,
it also decreased p-Akt levels. However, in presence of Isop,
sodium salicylate increased Akt phosphorylation, an effect
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Fig. 2 Role of adrenergic receptors in serum amyloid A (SAA) regulation
under control and stressful conditions. a–d Epinephrine (Epin) treatment
increased hepatic SAA1/2 and SAA3 mRNA levels, while pharmacologi-
cal stimulation ofα1- orβ1/2-adrenergic receptors (AR) by phenylephrine
(Ph) or isoprenalin (Isop) [α1- and β1/2-AR agonist, respectively) also
triggered the induction of SAA1/2 and SAA3 (a, b). Similarly, the serum
SAA apoprotein load was also increased by Epin, Ph, and Isop (c, d).
Note that the stimulation of α2-AR by dexmedetomidine (Dext) also
triggered the induction of SAA1/2 and SAA3 mRNA expression in the
liver, but to a lesser extent. e, f Treatment of animals with AR-antagonists
prior to stress [prazosin (Pr), α1-AR antagonist; propranolol (Prop), β1/2-
AR antagonist; atipamezole (Ati). α2-AR antagonist] blocked the stress-
driven increase of hepatic SAA1/2mRNA levels, while in contrast toβ1/2-
and α2-AR antagonists, single treatment with Pr, the α1-AR antagonist,
did not block the stress-evoked increase of SAA3 mRNA levels. All nu-
merical data are shown as mean + SEM; *P < 0.05, **P < 0.01,
***P < 0.001
Table 2 The impact of
epinephrine and different
adrenoceptor agonists on serum
cytokine levels
Repeated treatment IL-1β IL-6 TNFα
Control 20.0 ± 4.4 27.6 ± 5.3 11.3 ± 1.3
Epin (α/β-AR agonist) 102 ± 18.1*** 50.6 ± 8.2** 390 ± 186.9**
Ph (α1-AR agonist) 100 ± 13.8*** 107.6 ± 19.6*** 261 ± 54.8***
Dext (α2-AR agonist) 50.6 ± 12.6** 48.0 ± 7.4** 15.0 ± 2.9
Isop (β1/2-AR agonist) 124 ± 5.0*** 44.5 ± 1.4*** 179 ± 60.6***
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that is potentially associated with the SAA1/2 downregulation
that was observed inmice of this treatment group (see Fig. 3a).
A clearly different profile of sodium salicylate effect on Erk1/
2 phosphorylation (p-Erk1/2 levels) was found. In particular,
sodium salicylate did not alter the Ph-induced reduction of
Erk1/2 phosphorylation, while it strengthened that of Isop
(Fig. 3g, h; Supplementary Fig. 1).
Fenofibrate-induced blockade
of the adrenoceptor-mediated SAA upregulation
As previous studies have reported the involvement of perox-
isome proliferator-activated receptorα (PPARα, negative reg-
ulator of inflammatory response) in SAA production (Gervois
et al. 2004; Yamazaki et al. 2002); (Delerive et al. 1999; Staels
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Fig. 3 Differential impact of sodium salicylate in the AR-driven hepatic
SAA1/2 and SAA3 synthesis. a–c Pre-treatment of mice with sodium
salicylate (Sod. salicylate) prevented the AR-induced increase of hepatic
SAA1/2mRNA levels, which was evoked by different AR agonists, such
as Ph, Dext, and Isop (a). Sod. salicylate prevented the remarkable AR-
induced increase of serum IL-1β levels (b). The IL-1β inhibitor,
Anakinra, also blocked the AR-agonist induced hepatic SAA1/2 induc-
tion supporting a role for IL-1β in this AR-evoked SAA1/2 induction (c).
d–f In contrast to SAA1/2 effect, sod. salicylate markedly increased the
AR agonist triggered SAA3 induction; note that the higher effect of sod.
salicylate on SAA3 mRNA levels was found in animals following phar-
macological stimulation of their α1-AR with Ph (d). In parallel, sod.
salicylate, boosted TNFα serum levels, especially in the Ph-treated ani-
mals (e), whereas pre-treatment with the TNFα inhibitor, Infliximab,
completely blocked the sod. salicytate-driven increase of SAA3 mRNA
levels. These findings support the essential role of TNFα in SAA3 regu-
lation (f). g, h Western blot analysis of the hepatic p-Akt and p-Erk1/2
upon treatment with Ph or Isop in the presence or absence of sod. salic-
ylate (g). Treatment with sod. salicylate increased p-Akt in the liver of
mice following Ph (α1-AR agonist) or Isop (β1/2-AR agonist) treatment
(h). No effect of sod. salicylate was found on p-Erk1/2 levels in mice
following Ph treatment, but there was a sod. salicylate-driven reduction in
hepatic p-Erk1/2 of mice upon Isop treatment. All numerical data are
shown as mean + SEM; *P < 0.05, **P < 0.01, ***P < 0.001
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et al. 1998), we next investigated the impact of fenofibrate
(FEN), a PPARα-agonist with anti-inflammatory properties
(Won 2013), on AR-driven SAA regulation. We found that,
when administered simultaneously with Ph or Dext (α1- and
α2-AR agonist, respectively), FEN prevented the AR agonist-
induced upregulation of SAA1/2 and SAA3 in the liver
(Fig. 4a, b). Furthermore, this FEN inhibiting effect was ac-
companied by marked reduction of IL-1β serum levels
(Fig. 4c). Pearson’s coefficient correlation showed that this
FEN-induced blockade is highly correlated with serum IL-
1β and IL-6 levels (R2 = 0.883 and 0.834, respectively,
P < 0.001). However, FEN was unable to block the Isop
(β1/2-AR agonist)-induced upregulation of SAA1/2 and
SAA3 (Fig. 4a, b) suggesting that the protective role of FEN
against the AR-mediated upregulating effect on SAA does not
include that of β1/2-ARs. On the other hand, serum TNFα
levels were markedly increased in mice treated with both, Ph
and FEN, compared to mice treated with Ph alone (Fig. 4d).
Nonetheless, it is of interest to note that, whereas IL-1β and
TNFα serum levels were markedly decreased by FEN in mice
treated with Isop when compared to those treated with Isop
alone (Fig. 4c, d); apparently, FEN did not manage to block
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Fig. 4 Fenofibrate blocked the AR-stimulated SAA induction. a, b
Pre-treatment with Fenofibrate (FEN) has blocked the hepatic induc-
tion of SAA1/2 and SAA3 mRNA expression by α1- and α2-AR
agonists, but not that by β1/2-AR agonists. c, d The increase of
serum IL-1β levels induced by all three types of AR agonists was
blocked by FEN treatment (c). In contrast, the FEN-driven blockade
of the AR-triggered SAA3 induction was accompanied by increased
TNFα serum levels in mice under Ph treatment, and reduced TNFα
serum levels in those under Isop treatment (d). e, f Western blot
analysis showed that FEN increased the hepatic pAkt and pErk1/2
levels in mice following Ph treatment, while no effect was found in
total Akt and Erk levels. All numerical data are shown as
mean + SEM; *P < 0.05, **P < 0.01, ***P < 0.001
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the Isop-driven increase in SAA1/2 and SAA3 production.
These findings profoundly exclude a PPARα involvement in
the β1/2-AR-induced SAA1/2 and SAA3 synthesis (Fig. 4a,
b). Furthermore, it was found that the combined treatment of
FEN and Ph, markedly increased the phosphorylated levels of
Erk1/2 and Akt (Fig. 4e, f), suggesting an involvement of
these negative regulators in the FEN-mediated blockade of
the Ph-induced SAA1/2 mRNA expression (Fig. 4a).
Discussion
There is an increasing body of evidence supporting that the
dynamic equilibrium between immune system and CNS is
regulated by autonomic pathways with catecholamines hold-
ing key roles (Flierl et al. 2009; Sternberg 2006; Tracey 2002).
Accordingly, activation of SNS by stress or different drugs
could target immune cells (e.g., macrophages) that express
all types of ARs. The present findings are in line with those
of previous studies indicating the up-regulating effect of stress
on SAA (Bryleva et al. 2017; Collier et al. 2011; Turlo et al.
2015). They further support the involvement of different ARs
in the stress-driven synthesis of both SAA1/2 and SAA3 in the
liver, while total serum SAA protein load was also increased,
indicating an AR-mediated systemic increase of these acute
phase proteins. Previous studies indicated that catecholamines
released by stress regulate the inflammatory potential of the
immune cells by stimulating ARs and thus, triggering the
secretion of IL-1β, IL-6, and TNFα (Flierl et al. 2007, 2008,
2009). Therefore, the afore-mentioned increase in SAA syn-
thesis in the liver could be attributed to the AR-stimulated
cytokine release from the immune cells, such as macrophages
(Ghezzi and Sipe 1988; O’Brien et al. 2008)—see also Fig. 5).
This notion is further supported by the fact that direct stimu-
lation of hepatocyte AR signaling pathways, using primary
hepatocyte cultures treated with AR agonists, did not affect
SAA1/2 and SAA3 expression (data not shown). Nonetheless,
the contribution of hepatic AR-linked pathways should not be
excluded as the molecular chaperons, ApoE and α1-
antichymotrypsin, participating in the formation of amyloid
proteins, are missing from primary hepatocyte cultures (Ma
et al. 1994).
Furthermore, aiming to dissect the potentially differential
role of various ARs in the regulation of synthesis and secretion
of SAA1/2 and SAA3 proteins, this study suggests that, de-
spite the fact that the stress-driven SAA1/2 production re-
quires all three types of ARs monitored in this study (α1-,
α2-, β1/2-ARs), only the α2- and β1/2-AR driven pathways
appear to regulate the stress-evoked SAA3 synthesis (see
Fig. 2e, f). Furthermore, pharmacological activation of distinct
ARs also mimic, at least in part, the stress-triggered hepatic
production of SAA1/2 and SAA3 supporting their potential
contribution to SAA regulation. In this set of experiments
investigating the impact of distinct AR type activation on
SAA production, α1- and β1/2-AR exhibited a stronger effect
than that of α2-AR. It is noteworthy that during stress, adren-
aline and noradrenaline are released and stimulate all types of
ARs. It is known that α2-AR stimulation (by an agonist) re-
sults in inhibition of noradrenaline release and therefore, to
reduced stimulation of post-synaptic α1- and β1/2-ARs
(Cooper and Bloom 1996; Furchgott 1972; Langer 2015;
Lohse 2015; Fabbri and Moon 2016). On the contrary, α1-
and β1/2-AR agonists directly stimulate the post synaptic
ARs. Furthermore, the α2-ARs expressed on hepatic cell
membranes are linked to Gi proteins and inhibit the
cAMP/PKA/CREB signaling pathway, whereas the α1- and
β1/2-ARs are linked to Gs proteins and stimulate this pathway,
thus differently affecting SAA synthesis (Barneda-Zahonero
et al. 2009).
The present findings suggest a potential strong role for the
AR-triggered inflammatory response in SAA regulation.
Specifically, the AR-mediated SAA1/2 upregulation was
prevented by sodium salicylate (a non-steroidal anti-inflam-
matory drug), that could be attributed to the suppression of
various cytokines (e.g., IL-1β); this effect was highly corre-
lated to hepatic SAA1/2 expression. The critical role of IL-1β
in the AR-agonist-induced SAA1/2 upregulation was also
demonstrated using Anakinra (IL-1β inhibitor), which
blocked the upregulation of SAA1/2 triggered by all three
types of ARs. In contrast to IL6, the α1-AR-driven increase
of IL-1β (Ph treatment) was prevented by sodium salicylate, a
fact that further supports the direct involvement of IL-1β, but
not that of IL-6, in the α1-AR-driven SAA1/2 synthesis (see
Fig. 5).
Fibrates, such as fenofibrate, are hypolipidemic drugs,
widely used in lowering plasma triglyceride and cholesterol
levels in patients with hyperlipidemias (Gervois et al. 2004;
Yamazaki et al. 2002). Often, these patients suffer from car-
diovascular disorders and are treated with drugs targeting AR.
Fenofibrate also displays anti-inflammatory properties acting
as a negative regulator of genes involved in the inflammatory
response. Previous studies reported that FEN lowered the syn-
thesis of acute phase proteins via activation of the nuclear
receptor, peroxisome proliferator-activated receptor α
(PPARα) (Delerive et al. 1999; Gervois et al. 2004; Staels
et al. 1998). In this study, fenofibrate (FEN) blocked the α1-
and α2-AR-induced upregulating effect on SAA1/2 and
SAA3 synthesis, but not that mediated by β1/2-AR.
Moreover, when combined to α1/α2-AR agonist, FEN
blocked the hepatic SAA1/2 and SAA3 upregulation, a fact
that has been mainly correlated with the suppression of serum
IL-1β and IL-6 concentrations. It should be noted that, despite
the suppression of serum IL-1β, IL-6, and TNFα levels,
FEN did not prevent the Isop-induced SAA upregulation, in-
dicating that potentially, there is no crosstalk between the β-
AR-induced SAA upregulation and PPARα, cytokines, or
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other FEN-related pathways. Interestingly, the FEN-induced
blockade of the α1-AR stimulated SAA expression in the liver,
was accompanied with the activation of Erk1/2 and Akt-
related signaling pathways, which display a negative control
on SAA regulation (Fasshauer et al. 2004; Nguyen and Gao
1999). The sodium salicylate repressive impact on β1/2-AR-
driven SAA1/2 synthesis, could be also explained on the basis
of the negative control of PI3k/Akt signaling pathway on SAA
synthesis (Fasshauer et al. 2004; Lu et al. 2013; Nguyen and
Gao 1999) as the combined treatment of sodium salicylate and
the β1/2-AR agonist, Isop, markedly increased Akt phosphor-
ylation compared to that of Isop alone. The observed reduced
activation of Erk1/2 signaling in the liver of mice under this
combined treatment, appears not to effectively eliminate the
down-regulating effect on SAA1/2 triggered by the activation
of Akt.
Interestingly, the mechanisms regulating SAA3 seem to be
different from those regulating the production and secretion of
SAA1/2 (see also Fig. 5). In contrast to SAA1/2,
administration of sodium salicylate simultaneously with AR
agonists, mainly with Ph (α1-AR agonist), led to a robust
induction of hepatic SAA3 expression. This effect is profound-
ly triggered by TNFα that was highly elevated in serum, po-
tentially via the sodium salicylate-induced inhibition of COX2
(Taupin et al. 1993). Notably, inhibition of TNFα by
Infliximab blocked the upregulating effect of the combined
treatment using AR agonist and sodium salicylate on SAA3,
underscoring the involvement of TNFα in this regulatory
pathway. This effect is of a paramount significance as SAA3
is not only a well-known acute phase reactant, but also a
molecular link between insulin resistance, obesity, and cardio-
vascular disease (Fasshauer et al. 2004). Future studies should
clarify the presence (or not) of a cross-talk or counterbalance
between SAA1/2 and SAA3 production.
The present study investigated the effect of stress, a major
activator of SNS, on the regulation of SAA in the liver focus-
ing on adrenoceptor (AR)-linked pathways, major compo-
nents of the sympathoadrenal response to stress and targets
Fig. 5 Hypothetical model summarizing the impact of stress and different
ARs on serumA amyloid (SAA) synthesis. Exposure to repeated restraint
stress or its effectors, such as epinephrine (Epin) and norepinephrine
(NE), stimulate different adrenoceptors (AR) expressed in the immune
cells (e.g., macrophage and lymphocytes) that in turn, stimulate the re-
lease of pro-inflammatory cytokines, IL-1β, IL-6, and TNFα, which
trigger the synthesis of SAA1/2 and SAA3 in the liver of mice. In
particular, a significant role for α1- and β1/2-AR is primarily suggested
in the induction of SAA1/2 that may involve the release of IL-1β, as
drugs with anti-inflammatory properties, such as sodium salicylate, as
well as the IL-1β inhibitor Anakinra blocked this AR-related SAA1/2
induction. Notably, sodium salicylate further enhanced the SAA3 induc-
tion by α1-AR agonists, in a TNFα-dependent manner supporting an
interrelated balance in SAA proteins under AR stimulation
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of drugs used for the treatment of hypertension, asthma, angi-
na pectoris, heart failure, arrhythmias, prostatic hypertrophy,
glaucoma, and depression (Lalchandani et al. 2004;
Minneman and Esbenshade 1994; Virtanen 1989). Thus, the
findings of this study are of particular interest as indicate that
individuals repeatedly exposed to stress or treated with drugs
with sympathomimetic properties or directly targeting AR
(mainly those of α1- and β1/2-AR subtype), could exhibit
increased SAA synthesis in the liver, mediated by pro-
inflammatory cytokines (see Fig. 5). The stress and AR-
induced SAA1/2 upregulation can be prevented, in most
cases, by anti-inflammatory drugs. However, it should be not-
ed that the combined treatment using AR agonists and the
anti-inflammatory drug, sodium salicylate, could dramatically
increase SAA3 expression in the liver, triggered by the in-
creased TNFα release. In the long run, the increased produc-
tion and secretion of SAA could be connected with important
pathogenic precipitants of different disease states related to
stressful conditions, such as cardiovascular disorders.
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